Japan Gene Therapy Market Size, Share, and COVID-19 Impact Analysis, By Approach (In-Vivo, Ex Vivo), By Vector Type (Viral Vectors, Non-Viral Vectors), and Japan Gene Therapy Market Insights, Industry Trend, Forecasts to 2035

Japan Gene Therapy Market Insights Forecasts to 2035

• The Japan Gene Therapy Market Size Was Estimated at USD 159.36 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 19.47% from 2025 to 2035
• The Japan Gene Therapy Market Size is Expected to Reach USD 1128.16 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The Japan Gene Therapy Market Size is anticipated to Reach USD 1128.16 Million by 2035, Growing at a CAGR of 19.47% from 2025 to 2035. The market is primarily driven by Japans push for sustainable agriculture, limited arable land, and the need to boost crop productivity.

Market Overview

Japan Gene Therapy Market Size is an advanced medical approach that involves modifying or replacing faulty genes within a patients cells to treat or potentially cure diseases. There are several opportunities in Japan, with a growing emphasis on customized treatment, particularly in light of the countrys aging population and high rate of uncommon and hereditary disorders. Curative treatments for diseases like hemophilia, spinal muscular atrophy, and several hereditary retinal illnesses are much sought after. In order to create a favorable climate for research and commercialization, the Japanese government is also investing in precision medicine and encouraging partnerships between government, industry, and academia.

Report Coverage

This research report categorizes the market for the Japan gene therapy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan gene therapy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan gene therapy market.

Driving Factors

Japan has historically been at the forefront of pharmaceutical and biotechnology innovation, and this is also true in the field of gene therapy. The quick development of viral vector-based gene delivery systems and gene editing methods like CRISPR-Cas9 has created new opportunities for gene therapy research. Japanese businesses and academic organizations are using these technologies to investigate possible cures for a variety of hereditary illnesses, including uncommon ones and those for which there are currently no effective therapies.  As gene treatments continue to show promise in clinical studies, additional gene therapy items have been approved by Japans regulatory agency, the Pharmaceuticals and Medical Devices Agency (PMDA). The market benefits greatly from these approvals.

Restraining Factors

Despite the enormous potential health advantages of gene therapies, the high costs of development and treatment are anticipated to be a substantial obstacle to the markets expansion in Japan. Many patients cannot afford the enormous expenses of creating, producing, and delivering gene treatments, particularly in nations with more severe economic constraints like Japan.

Market Segmentation

The Japan-gene therapy market share is classified into approach and vector type.

• The in-vivo segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan gene therapy market is segmented by approach into in-vivo, ex vivo. Among these, the in-vivo segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The therapeutic gene is directly injected into the patients body during in vivo gene therapy; usually, a viral vector is used to deliver the gene to the target cells.

• The viral vectors segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Japan gene therapy market is segmented by vector type into viral vectors, non-viral vectors. Among these, the viral vectors segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This dominance is due to their high transfection efficiency and proven clinical success, especially in treating oncological and rare genetic disorders.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan gene therapy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Alnylam Pharmaceuticals, Inc.
• NOVARTIS AG
• Sarepta Therapeutics, Inc
• Krystal Biotech, Inc.
• CSL
• Bluebird Bio, Inc.
• SPARK THERAPEUTICS
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan Gene Therapy Market based on the following segments:

Japan Gene Therapy Market, By Approach

• In-Vivo
• Ex Vivo

Japan Gene Therapy Market, By Vector Type

• Viral Vectors
• Non-Viral Vectors